. "Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
Merz, D.C., A.Scheid, and P.W.Choppin. 1980. Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J. Exp. Med. 151:275–288.
National Institute of Allergy and Infectious Diseases. 1985. Program for Accelerated Development of New Vaccines. Progress Report. Bethesda, Md.: National Institutes of Health.
Parrott, R.H., A.J.Vargosko, H.W.Kim, J.A.Bellanti, and R.M. Chanock. 1962. III. Myxoviruses parainfluenza. Am. J. Public Health 52:907–917.
Portner, A. 1981. The HN glycoprotein of Sendai virus: Analysis of site(s) involved in hemagglutinating and neuraminidase activities. Virology 115:375–384.
Scheid, A., and P.W.Choppin. 1974. Identification of biologicalactivities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis and infectivity by proteolytic cleavage of an inactive precursor protein of Sendai Virus. Virology 57:475–490.
Scheid, A., A.L.Caliguiri, R.W.Compans, and P.W.Choppin. 1972. Isolation of paramyxovirus glycoprotein. Association of both hemagglutinating and neuraminidase activities with the larger SV5 glycoprotein. Virology 50:640–652.
Smith, C.B., R.H.Purcell, J.A.Bellanti, and R.M.Chanock. 1966. Protective effect of antibody to parainfluenza type 1 virus. N. Engl. J. Med. 275:1145–1152.
Wigley, F.M., M.H.Fruchtman, and R.H.Waldman. 1970. Aerosol immunization of humans with inactivated parainfluenza type 2 vaccine. N. Engl. J. Med. 283:1250–1253.